laoxinglin 老杏林
Dan Shen (Red Sage) illustration

The Herb Cabinet 本草

丹参 dān shēn

Salvia miltiorrhiza · red sage root

Slightly cold Bitter HeartPericardiumLiver

“The crimson root the tradition trusted with the heart itself. One herb, they said, with the powers of four — though the fine print matters more here than anywhere.” — Lao Xinglin

What the tradition says

The red root of a Chinese sage, named as if it were a crimson cousin of ginseng (shen). Dan shen is the tradition's great blood mover for the chest: stabbing chest and abdominal pain, masses, and menstrual disorders from stasis, plus a side gift of cooling the blood and calming a vexed spirit[1]. An old saying claims one herb does the work of the whole Four Substances blood formula. In modern China it became an institution: dan shen preparations are among the most prescribed cardiovascular herbals on Earth.

What the research says

Enormously studied, honestly mixed. The tanshinones and salvianolic acids show real cardiovascular pharmacology in the laboratory, and Chinese clinical use is vast — but rigorous Western trials are sobering: a randomized double-blind crossover trial of the water extract found no benefit on a broad panel of cardiovascular risk factors[3]. Reviews of the interaction literature, meanwhile, treat it as one of the best-documented herb-drug offenders[2].

Where to be careful — read this one

In the pharmacy

Brick-red to purple-red roots, sold sliced; the color is the tanshinones. Classical pairing: with san qi for the chest — a duo modern patent medicines still bottle.

References

  1. Bensky, Clavey & Stöger, Chinese Herbal Medicine: Materia Medica, 3rd ed., Eastland Press, 2004.
  2. Zhou X, et al. Salvia miltiorrhiza roots against cardiovascular disease: consideration of herb-drug interactions. Biomed Res Int. 2017;2017:9868694. https://pmc.ncbi.nlm.nih.gov/articles/PMC5394393/
  3. Siebel AL, et al. Salvia miltiorrhiza root water-extract (Danshen) has no beneficial effect on cardiovascular risk factors: a randomized double-blind cross-over trial. PLoS One. 2015;10(7):e0128695. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508048/

Lao Xinglin seal Reviewed 2026-08-26